Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib + Ramucirumab in Metastatic Esophageal/Gastroesophageal Junction Carcinomas
NCT04921904Phase 2Completed
- Sponsor
- Baylor Scott & White Research Institute
- Start
- Jun 2021
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of abemaciclib in esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma, sponsored by Baylor Scott & White Research Institute. Started Jun 2021; status: completed.
02
Drugs
abemaciclib
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04921904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04921904.